Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
B Shariat-Madar1, D Kolte2, A Verlangieri2, Z Shariat-Madar21College of Literature, Science, and the Arts, University of Michigan, Ann Arbor MI, USA; 2School of Pharmacy, Department of Pharmacology, University of Mississippi, University, MS, USAAbstract: Recently, we serendipitously discovered that...
Main Authors: | B Shariat-Madar, D Kolte, A Verlangieri, et al |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-04-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Online Access: | http://www.dovepress.com/prolylcarboxypeptidase-prcp-as-a-new-target-for-obesity-treatment-a4269 |
Similar Items
-
Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
by: Shariat-Madar Z, et al.
Published: (2010-04-01) -
A Cross-Sectional Study of KLKB1 and PRCP Polymorphisms in Patients with Cardiovascular Disease
by: Haley R. Gittleman, et al.
Published: (2016-04-01) -
Clinical Relevance of Plasma Prolylcarboxypeptidase Level in Patients with Idiopathic Acute Optic Neuritis
by: Jong-Heon Kim, et al.
Published: (2024-04-01) -
Association of polymorphisms in prolylcarboxypeptidase and chymase genes with essential hypertension in the Chinese Han population
by: Yanrui Wu, et al.
Published: (2013-09-01) -
Prolylcarboxypeptidase Alleviates Hypertensive Cardiac Remodeling by Regulating Myocardial Tissue Angiotensin II
by: Binh Y. Nguyen, et al.
Published: (2023-06-01)